Ensera Launches an Innovative Alliance Network for Injectable Drug Development

Ensera Launches an Alliance Network for Injectable Drug Development

Ensera, a globally recognized Contract Development and Manufacturing Organization (CDMO), has recently announced the launch of the Ensera Alliance Network. This new initiative aims to facilitate the market introduction of injectable pharmaceutical programs by uniting key players within the medical technology sector. The alliance includes prominent companies specializing in injection platforms such as SHL Medical, the Stevanato Group, and Ypsomed, as well as fill-finish experts Argonaut Manufacturing Services and American Injectables.

The landscape of combinational product launches can be complex, often requiring pharmaceutical companies to coordinate with multiple specialized suppliers across various stages—from device platform assembly to final packaging. Each transition can potentially increase complexity and slow down the development process, particularly when responsibilities, processes, and schedules are misaligned.

To combat these challenges, the Ensera Alliance Network is designed to enhance connections across critical phases of the supply chain specifically pertaining to combination products. This assists pharmaceutical companies in better coordinating their programs related to device platforms, fill-finish services, assembly, and packaging, ultimately speeding up their journey towards commercial availability.

Bobby O'Connor, Chief Commercial Officer at Ensera, emphasizes the rationale behind this new network: “Too many combination product programs are stalled by poorly connected suppliers and challenging handoffs. The Ensera Alliance Network brings together trusted specialists within a better-coordinated, responsive model, helping our customers simplify their launch process, reduce risks, and work swiftly towards hitting the market.”

In similar terms, Darren Hieber, VP of Alliance Partnerships at Ensera, noted, “This network is built on established relationships, shared experiences, and a practical understanding of how each organization operates. By connecting partners from medical device platforms, fill-finish services, assembly, and packaging, we can better address individual program needs, identify challenges early, and support customers in transitioning to commercial supply.”

Ensera's plan is to expand the network over time, intending to include organizations whose capabilities, standards, and approaches complement those of existing members alongside the evolving needs of their clients. Importantly, joining the Ensera Alliance Network is non-exclusive; Ensera and its network participants will remain independent entities, allowing clients to work with each organization either collectively or individually.

Ensera stands out as a global CDMO that assists pharmaceutical and medical device companies with product development, manufacturing, assembly, labeling, and secondary packaging of injectable formats, including injectors and pre-filled syringes. Their flexible, GMP-compliant facilities in Europe, the USA, and Asia are optimized for small to medium batch sizes and reinforced by integrated quality systems as well as a robust cold chain infrastructure. As an approved assembly partner for leading injector platforms, Ensera combines its medical device and pharmaceutical expertise to ensure efficient and compliant supply routes for combination products.

For more information on the Ensera Alliance Network, visit their official website: Ensera.

Members of the Ensera Alliance Network: